Thus, further studies are urgently required to verify our findings and to compare the safety and efficacy of anti‐EGFR mAbs plus chemotherapy with chemotherapy alone for the treatment of RM‐NPC. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.